Getting away from GLP-1s, Pharmaceutical Executive features CEO Scott Brunner and Chief Advocacy Off...
Reuters, like many other media outlets, covered Novo Nordisk’s request that the FDA add semaglutide ...
A different angle: CBS News quoted Scott on the issue of how the FDA decides when a shortage is reso...
UK-based pharmaphorum is covering the GLP-1 issue on this side of the pond — specifically Lilly’s an...
APC CEO Scott Brunner appeared on the Scripps News show “America On The Docket,” talking about the “...
The Hill covers the fallout from the FDA’s taking tirzepatide off the shortage list — especially how...
Specialty Pharmacy Continuum has a great piece explaining why a longer “tail” for 503A pharmacies wo...
Wired wrote about “The Crackdown on Compounded GLP-1 Meds,” where it made clear that it doesn’t quit...
Kudos to Wired for its piece, “A Major GLP-1 Drug Shortage Is Over. Some Patients Aren’t Celebrating...
In a piece on the battle between Eli Lilly and compounding pharmacists over tirzepatide — notably th...